These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

295 related items for PubMed ID: 15690331

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. Podoplanin is a useful marker for identifying mesothelioma in malignant effusions.
    Hanna A, Pang Y, Bedrossian CW, Dejmek A, Michael CW.
    Diagn Cytopathol; 2010 Apr; 38(4):264-9. PubMed ID: 20146302
    [Abstract] [Full Text] [Related]

  • 23. The value of epithelial membrane antigen expression in separating benign mesothelial proliferation from malignant mesothelioma: a comparative study.
    Saad RS, Cho P, Liu YL, Silverman JF.
    Diagn Cytopathol; 2005 Mar; 32(3):156-9. PubMed ID: 15690334
    [Abstract] [Full Text] [Related]

  • 24. Immunocytochemistry in the differential diagnosis of effusions: use of logistic regression to select a panel of antibodies to distinguish adenocarcinomas from mesothelial proliferations.
    Frisman DM, McCarthy WF, Schleiff P, Buckner SB, Nocito JD, O'Leary TJ.
    Mod Pathol; 1993 Mar; 6(2):179-84. PubMed ID: 8483888
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Immunohistochemical phenotype of malignant mesothelioma: predictive value of CA125 and HBME-1 expression.
    Bateman AC, al-Talib RK, Newman T, Williams JH, Herbert A.
    Histopathology; 1997 Jan; 30(1):49-56. PubMed ID: 9023557
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Multiple-marker immunohistochemical phenotypes distinguishing malignant pleural mesothelioma from pulmonary adenocarcinoma.
    Brown RW, Clark GM, Tandon AK, Allred DC.
    Hum Pathol; 1993 Apr; 24(4):347-54. PubMed ID: 7684019
    [Abstract] [Full Text] [Related]

  • 30. Carbohydrate antigen expression in primary tumors, metastatic lesions, and serous effusions from patients diagnosed with epithelial ovarian carcinoma: evidence of up-regulated Tn and Sialyl Tn antigen expression in effusions.
    Davidson B, Berner A, Nesland JM, Risberg B, Kristensen GB, Tropé CG, Bryne M.
    Hum Pathol; 2000 Sep; 31(9):1081-7. PubMed ID: 11014575
    [Abstract] [Full Text] [Related]

  • 31. The use of histological and immunohistochemical markers to distinguish pleural malignant mesothelioma and in situ mesothelioma from reactive mesothelial hyperplasia and reactive pleural fibrosis.
    Cury PM, Butcher DN, Corrin B, Nicholson AG.
    J Pathol; 1999 Oct; 189(2):251-7. PubMed ID: 10547583
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. High levels of tumor markers in pleural fluid correlate with poor survival in patients with adenocarcinomatous or squamous malignant effusions.
    Bielsa S, Esquerda A, Salud A, Montes A, Arellano E, Rodríguez-Panadero F, Porcel JM.
    Eur J Intern Med; 2009 Jul; 20(4):383-6. PubMed ID: 19524179
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Comparison of three cytologic preparation methods and immunocytochemistries to distinguish adenocarcinoma cells from reactive mesothelial cells in serous effusion.
    Ueda J, Iwata T, Ono M, Takahashi M.
    Diagn Cytopathol; 2006 Jan; 34(1):6-10. PubMed ID: 16355377
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Utility of a CEA, CD15, calretinin, and CK5/6 panel for distinguishing between mesotheliomas and pulmonary adenocarcinomas in clinical practice.
    Mohammad T, Garratt J, Torlakovic E, Gilks B, Churg A.
    Am J Surg Pathol; 2012 Oct; 36(10):1503-8. PubMed ID: 22982894
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Immunocytochemical panel for distinguishing between carcinoma and reactive mesothelial cells in body cavity fluids.
    Politi E, Kandaraki C, Apostolopoulou C, Kyritsi T, Koutselini H.
    Diagn Cytopathol; 2005 Mar; 32(3):151-5. PubMed ID: 15690338
    [Abstract] [Full Text] [Related]

  • 40. Vimentin, carcinoembryonic antigen and keratin in the diagnosis of mesothelioma, adenocarcinoma and reactive pleural lesions.
    al-Saffar N, Hasleton PS.
    Eur Respir J; 1990 Oct; 3(9):997-1001. PubMed ID: 1705232
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 15.